AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06780774 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Blend containing 17mg Marigold Extract and Brown rice flour. Other Names: Placebo Treatment
Study NCT06780644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple combination cream
Description: 1. Apply sunscreen SPF ≥30 in the morning on 2 knuckles~2. Apply triple combination cream containing hydroquinone 40 mg, tretinoin 0.5 mg, and fluocinolone acetonide 0.1 mg at night all over the face except the area around the eyes, 1 fingertip unit (FTU) or 1 knuckle.
Study NCT06102148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF Group
Description: Exercise training and PNF training
Study NCT06102148 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: Exercise training
Study NCT05197062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-aticaprant
Description: 14C-aticaprant will be administered orally as capsule on Day 1.
Study NCT05346367 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SRT
Description: SRT
Study NCT04677517 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modification of active microphone positioning
Description: Patient will pass the experimental tests described above with 3 different active microphone positions :~* on the cochlear implant processor;~* on the antenna~* in front of the external ear canal~Patient will pass the tests 1 week after each microphone position change, so that they can get used to the new position in their everyday life.
Study NCT04677517 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPHERE protocol
Description: Patient's 3D localization in noise will be assessed thnks to a 3D localization system called SPHERE based on virtual reality.~Data from spatial hearing perception will be recorded in three-dimensional space (azimuth, elevation, and depth). First, the pointing error will be computed separately for azimuth, elevation, and depth, in terms of constant error (absolute and signed) and variable error. Then, these separate errors will be combined into a cumulative error 3d-D (the 3d-D value), hence summarizing all three space dimensions, and taking into account absolute and variable error in one measure.
Study NCT04677517 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: French Matrix Test
Description: This test assesses the intelligibility threshold defined as the noise level (in decibels) for which the subject can repeat 50% of the words heard (in dichotic listening), resulting in an Speech Recognition Threshold (SRT) value
Study NCT04677517 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaire
Description: The Speech, Spatial and Qualities of Hearing Scale short-form with 15 items (SSQ15) questionnaire is performed in order to evaluate auditory abilities of patients in different daily life situations.
Study NCT05346367 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fSRT
Description: fSRT
Study NCT05510973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced package for AHD care
Description: The enhanced package of AHD care includes CD4 and tuberculosis lipoarabinomannan (TB-LAM) tests and the initiation of patients on TB prophylaxis \[TPT and CPT\], offered through a hub-and-spoke facility system, with continuous quality improvement (QI)
Study NCT06318416 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: urine spectrophotometry for rifampin absorbance
Description: All participants will received conventional weight-based TB therapy, standard of care for active TB disease. After enrollment, participants will be randomized to early Day 14 or delayed Day 21 dose modification of rifampin informed by urine spectrophotometry where absorbance is determined above or below a threshold. Below a threshold, single tablets of rifampin are added to conventional fixed drug combination standard of care, above a threshold, no additional rifampin is added. Dose adjustment of rifampin may be up to \~30mg/kg and will be continued through day-56.
Study NCT04677517 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Likert scale
Description: This subjective evaluation will be added to evaluate difficulties and self-confidence felt by participants during the SPHERE protocol and the French Matrix Test.
Study NCT05214716 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: FilmArray Pneumonia panel
Description: A rapid molecular diagnostic test designed to detect 27 bacterial and viral species and 6 major resistance genes from respiratory specimens.
Study NCT06780644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple combination cream
Description: 1. Apply sunscreen SPF ≥30 in the morning on 2 knuckles~2. Apply triple combination cream containing mometasone furoate 0.1%, hydroquinone 4%, tretinoin 0.05% at night all over the face except the area around the eyes, 1 fingertip unit (FTU) or 1 knuckle
Study NCT06780696 — intervention group
Intervention type: DEVICE
Intervention: SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator
Description: Radiofrequency ablation of renal arterial sympathetic nerves
Study NCT06335927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC-GEMOX+Cadonilimab+Regorafenib
Description: HAIC-GEMOX: Gemcitabine 1000mg/m2 on Day 1 + Oxaliplatin 85mg/m2 on Day 1, every 3 weeks (Q3W), for up to 6 treatment cycles in combination with Cadonilimab (6mg/kg, D2, Q3W) and Regorafenib (80mg QD, Q3W)
Study NCT03947905 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual visit
Description: Type of visit
Study NCT06166862 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action observation and motor imagery therapy for rehabilitation
Description: Action observation; Patients will watch some exercises accompanied by music from a previously prepared video for 10 minutes. Exercises include 8-10 repetitions of abduction-adduction, horizontal abduction-adduction, flexion-extension and supination-pronation movements for the upper extremity, and stepping, forward-backward stepping, side stepping and ankle dorsiflexion movements for the lower extremity.~Motor imagery training; Patients will be asked to visualize the actions they watched in their minds for 10 minutes.~Then the patients will watch the video again and will be asked to perform the exercises while watching.
Study NCT06166862 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham action observation and motor imagery therapy for rehabilitation
Description: Sham action observation; Patients will watch a video consisting of static nature photographs for 10 minutes with the same music.~Sham motor imaginary; Patients will think about the video they watched for 10 minutes.~Then, they will watch another video in which the exercises are performed only once, and they will be asked to do the exercises. They will be given enough time to do 8-10 repetitions.
Study NCT04779593 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical examination
Description: Clinical data will be recorded (general clinical examination, height, weight, blood pressure,heart beat, alcohol and tobacco consumption, antecedent) as well as concurrent medication at each follow-up visit.
Study NCT04779593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical examination
Description: Clinical data will be recorded (general clinical examination, height, weight, blood pressure,heart beat, alcohol and tobacco consumption, antecedent) as well as concurrent medication at each follow-up visit.
Study NCT04779593 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SF36 questionnaire
Description: At D0, M12 and M24. This 36 item patient reported survey of patient's health is the most commonly used and validated health survey instrument for appraising quality of life.~Items are grouped in 8 scaled scores exploring multiple dimension of global health (vitality, physical functioning, bodily pain, general health, perceptions, physical role functioning, emotional role functioning, social role functioning, mental health).~Scoring will be performed as recommended by the SF-36 instruction manual to create the eight scale scores. Furthermore, these subscales sum to obtain the total SF-36 score and will be summarized into two composite scores (physical and mental quality of life).
Study NCT04856475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: As per investigator's choice, eligible subjects in all cohort will receive:~* Neratinib, administered continuously at a dose of 240 mg orally once a day in combination with:~  * Capecitabine, administered continuously at a dose of 750 mg/m2, orally, twice a day (=daily dose of 1500 mg/m2) from D1 toD14 (21 days cycle) (preferred option) or~ * Vinorelbine, I.V. 25 mg/m2 on D1 and D8 (21 days cycle) or~ * Paclitaxel, I.V. 80 mg/m2 on D1, D8, and D15 (21 days cycle) Important note: The possibility to combine trastuzumab, loading dose 8 mg/kg IV followed by 6 mg/kg Q3W IV or SC 600 mg Q3W, to one of these above treatments is left at investigator's discretion OR~* Neratinib, administered continuously at a dose of 160 mg, orally, once a day in combination with:~  * T-DM1, I.V. 3.6mg/m2 on D1 (21 days cycle) (preferred option)
Study NCT05702255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active acupressure
Description: Participants will receive training (2 sessions, 2 days a part) by a training researcher. Patients will be taught on the acupoints location and the acupressure technique. Participants will be verified for the correct location of the acupoints, acupressure technique and strength. Participants will be instructed to use thumb or middle finger to self- press each acupoint using circular movements. The force of pressing must be sufficiently strong but still within a comfortable range. A lubricant will be uses to decrease friction between the acupoints and the finger. Follow up evaluation will be at the end of the week 2 and week 4 .The training researcher will make weekly calls to remind participants to perform acupressure and to answer questions
Study NCT05702255 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acuptressure
Description: The same protocol as the active acupressure group.
Study NCT06248294 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CT follow-up
Description: Computed tomography angiography assessment of BAV-related aorthopathy
Study NCT04779593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SF36 questionnaire
Description: At D0, M12 and M24. This 36 item patient reported survey of patient's health is the most commonly used and validated health survey instrument for appraising quality of life.~Items are grouped in 8 scaled scores exploring multiple dimension of global health (vitality, physical functioning, bodily pain, general health, perceptions, physical role functioning, emotional role functioning, social role functioning, mental health).~Scoring will be performed as recommended by the SF-36 instruction manual to create the eight scale scores. Furthermore, these subscales sum to obtain the total SF-36 score and will be summarized into two composite scores (physical and mental quality of life).
Study NCT06559761 — intervention group
Intervention type: PROCEDURE
Intervention: Hepatectomy
Description: According to guideline recommended procedure of hepatectomy
Study NCT05426395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B12 2.6 µg
Description: There are four groups of women (n = 20 total) who will receive B12 dosing once daily, including group 1a (sufficient baseline B12, pregnant), group 1b (sufficient baseline B12, non-pregnant), group 1c (insufficient baseline B12, pregnant), and group 1d (insufficient baseline B12, non-pregnant).
Study NCT05426395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B12 10 µg
Description: There are two groups of women (n = 10 total) who will receive B12 dosing once daily, including group 2a (sufficient baseline B12, pregnant) and group 2b (insufficient baseline B12, pregnant).
Study NCT05426395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B12 50 µg
Description: The participants (n = 20 total) will be randomly assigned to receive either a once per day B12 dose or a twice per day B12 dose. The four groups at this dose level include: group 3a (sufficient baseline B12, pregnant, Q12), group 3b (sufficient baseline B12, Q24), group 3c (insufficient baseline B12, pregnant, Q12), group 3d (insufficient baseline B12, Q24).
Study NCT06339424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg will be administered as an IV infusion on Day 1 of each cycle, with cycles occurring every 3 weeks. The initial dose will be delivered over 60 (± 15) minutes, and if well-tolerated, subsequent infusions may be given over 30 minutes. For patients who achieve a complete response (CR) within one year of treatment, atezolizumab should be continuously used for a year. For patients who experience a partial response (PR), atezolizumab should be continued until achieving CR or experiencing progressive disease (PD). Patients with stable disease should receive atezolizumab for 6 months. In the case of PD, atezolizumab should be discontinued at the time when PD is confirmed.
Study NCT06339424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/kg will be administered as an IV infusion on Day 1 of each 3-week cycle. The initial dose will be delivered over 90 minutes (±15 minutes), and if well-tolerated, subsequent infusions may be given over 60 minutes. For patients who achieve a complete response (CR) within one year of treatment, bevacizumab should be continuously used for a year. In the case of patients experiencing a partial response (PR), bevacizumab should be continued until achieving CR or experiencing progressive disease (PD). Patients with stable disease should receive bevacizumab for 6 months. In the event of PD, bevacizumab should be discontinued when PD is confirmed. Temporary withholding or dose reduction of bevacizumab is permitted if patients experience adverse events such as bleeding episodes, severe hypertension, or proteinuria at the discretion of the treating physician.
Study NCT06339424 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photon radiotherapy
Description: * 39.6-72.6 Gy in 22 fractions for tumors ≤1 cm from the hepatic hilum, bowel, and heart.~* 30-66 Gy in 10 fractions for tumors >1 cm from the hepatic hilum, bowel, and heart.~* 27.5-50 Gy in 5 fractions using stereotactic body radiation therapy (SBRT) techniques
Study NCT04779593 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AIMS2_SF questionnaire
Description: At D0, M12 and M24. The Arthritis Impact Measurement Scales 2 Short Form (AIMS2-SF) is a specific tool to measure changes in global health, pain, mobility and social function in patients with arthritis. It was described in 1992 in patients with rheumatoid arthritis and osteoarthritis and include 26 items that are summarized in scales according to a predefined scoring system: mobility, physical activity (walking, bending, lifting), dexterity, household activity (managing money and medications, housekeeping), social activities, activities of daily living, pain, depression, and anxiety. The French translation has been validated and this questionnaires has been widely used in the rheumatology field to assess quality of life of patients with arthritis. Because HFE related arthropathy is very similar to osteoarthritis this questionnaire is ought to be adequate in this setting.
Study NCT06405243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myoinositol
Description: Myoinositol decreases insulin resistance and consequently increased intracellular glucose uptake, restore the metabolic profile and induce ovulation in PCOS patients with infertility, in addition to its good safety profile
Study NCT06405243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chromium
Description: chromium picolinate may potentiates the therapeutic effect of letrozol on pituitary hormones (FSH and LH), improvement of ovulation, normalization of Estrogen level, improvement of endometrial thickness related to ovulation
Study NCT06405243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: l-arginine
Description: new antioxidant that minimizes the inflammatory reaction, the hormonal imbalance, and the metabolic disturbances in PCO
Study NCT06405243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: selective aromatase inhibitor
Study NCT04566497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No stress testing
Description: No stress testing during the patient follow up (up to 48 months) if the patient remains asymptomatic
Study NCT04566497 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stress testing
Description: Systematic annual stress testing during the patient follow up (up to 48 months)
Study NCT06780436 — intervention group
Intervention type: DEVICE
Intervention: 3D Transcranial Ultrasound Brain Imaging
Description: The system implements a proprietary transcranial imaging methodology, which measures the profile of the skull bone and the speed of sound in it to accurately focus the ultrasound energy from a phased array probe through the bone in order to detect hematoma boundaries with resolution normally obtainable only through the open skull.
Study NCT05518591 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion Focused Therapy (CFT) combined with Breathing Pattern Retraining (BPR)
Description: Study participants in the experimental arm of the study are being asked to take part in a 6-week, virtual, psychological therapy group involving compassion focused therapy and breathing pattern retraining. This group involves exercises in practicing self-compassion, emotional regulation, and breathing retraining. Each group session lasts less than two hours, per week.
Study NCT06346808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oncolytic virus Plus Anti-PD1 and Chemotherapy
Description: Oncolytic virus，Camrelizumab ，AG（Gemcitabine +Capecitabine ）
Study NCT04230720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systane Complete
Description: 1 drop 4 times a day for 14 days
Study NCT04697381 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: somatropin - GH naïve pediatric cohort
Description: somatropin 0.245 mg/kg/week
Study NCT04697381 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: somatropin - GH treated cohort
Description: somatropin 0.084 mg/kg/week
Study NCT04697381 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: somatropin - adult cohort
Description: somatropin 0.084 mg/kg/week
Study NCT06134453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki/Sham Reiki
Description: Reiki will be applied to the patients by the research nurse who is at the Reiki master level. Sham Reiki will remain in the same position and for the same duration as if Reiki was performed by a healthcare professional who has not received Reiki training, but Reiki energy will not be given to the patient. No intervention will be made to the control group.
Study NCT06134453 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Reiki/Sham Reiki
Description: Reiki will be applied to the patients by the research nurse who is at the Reiki master level. Sham Reiki will remain in the same position and for the same duration as if Reiki was performed by a healthcare professional who has not received Reiki training, but Reiki energy will not be given to the patient. No intervention will be made to the control group.
Study NCT04652622 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mindful Garden
Description: Mindful Garden is an interactive digital behavior modification platform utilizing inbuilt sensors and screen based delivery system. The platform delivers calming visual output of real nature video layered with hyper-real animations of growing and receding flowers and butterflies in flight in a volume directly responsive to measured patient activity. Patient movement and vocalization are the surrogate markers for agitation and using proprietary algorithms drive onscreen content.
Study NCT04955158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 75 µg dexmedetomidine soaked pharyngeal pack (Group D) putted in the posterior pharyngeal wall after induction of anesthesia and ETT.
Study NCT04955158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 50 mg ketamine soaked pharyngeal pack (Group K) putted in the posterior pharyngeal wall after induction of anesthesia and ETT.
Study NCT04955158 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: saline 0.9%
Description: 20 ml 0.9% saline soaked pharyngeal pack (Group C) putted in the posterior pharyngeal wall after induction of anesthesia and ETT.
Study NCT04935580 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC012F injection
Description: GC012F injection is an autologous dual CAR-T targeted BCMA and CD19. A single infusion of CAR-T cells will be administered intravenously.
Study NCT06205264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training at high and low speeds.
Description: The training program will last for 8 weeks with a frequency of 3 sessions per week. Session duration will be 40-60 minutes, depending on the week within the developed schedule. To form the groups, participants will be randomly divided into two groups. On one hand, the explosive group will perform exercises in less time with faster movements, while the conventional group will execute the training with slower movements. The entire session will be designed and supervised by three exercise specialists. Each child must have a written informed consent completed by their parent/guardian.~Three days of strength training will be conducted following WHO recommendations, emphasizing multi-joint exercises.
Study NCT05098743 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medisafe smartphone mobile application
Description: The medication adherence smartphone mobile application (app) will provide reminders to take individual patient medications and offers medication information and a social support feature.